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Available online 28 October 2016Glucose-stimulated insulin secretion (GSIS) by pancreatic β cells is biphasic. However, the physiological signiﬁ-
cance of biphasic GSIS and its relationship to diabetes are not yet fully understood. This study demonstrated that
impaired ﬁrst-phase GSIS follows fasting, leading to increased blood glucose levels and brain glucose distribution
in humans. Animal experiments to determine a possible network between the brain and β cells revealed that
fasting-dependent hyperactivation of AMP-activated protein kinase in the hypothalamus inhibited ﬁrst-phase
GSIS by stimulating the α-adrenergic pancreatic nerve. Furthermore, abnormal excitability of this brain-β cell
neural axis was involved in diabetes-related impairment of ﬁrst-phase GSIS in diabetic animals. Finally, pancre-
atic denervation improved ﬁrst-phase GSIS and glucose tolerance and ameliorated severe diabetes by preventing
β cell loss in diabetic animals. These results indicate that impairedﬁrst-phase GSIS is critical for brain distribution
of dietary glucose after fasting. Furthermore, β cells in individuals with diabetes mistakenly sense that they are
under conditions that mimic prolonged fasting. The present study provides additional insight into both β cell
physiology and the pathogenesis of β cell dysfunction in type 2 diabetes.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Insulin hasmany physiological roles, including anabolic action ondi-
etary energy storage, which is important for overcoming upcoming
fasting periods (Cahill, 1971). However, the anti-catabolic action of in-
sulin must be suppressed during fasting to avoid a life-threatening hy-
poglycemic event. Therefore, the precise systems that monitor fasting
or feeding states and subsequently control insulin action are essential
for maintaining whole-body glucose homeostasis to overcome fasting.
Dysregulation of these systems contributes to type 2 diabetes pathogen-
esis (Kadowaki, 2000; Kahn and White, 1988; Kulkarni et al., 1999;
Seino et al., 2011). Therefore, more complete knowledge of the relation-
ship between insulin physiology and fasting will contribute to a better
understanding of type 2 diabetes and may lead to effective therapeutic
options.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is biphasic (Porte and Pupo, 1969; Curry et al., 1968; Seino et al.,
2011). Since the ﬁrst report of biphasic GSIS by Curry et al. in 1968,
the dynamics of biphasic GSIS have been examined under both normal
physiological conditions and in the pathogenesis of type 2 diabetes
(Pfeifer et al., 1981; Polyzogopoulou et al., 2003; Weyer et al., 1999).
The current consensus holds that a deﬁcient ﬁrst-phase GSIS as deter-
mined by a frequently sampled intravenous glucose tolerance test
(FSIVGTT) represents the earliest identiﬁable change to β cells in the
course of type 2 diabetes. First-phaseGSIS in the FSIVGTT is closely asso-
ciated with the early insulin response to oral glucose ingestion (Caumo
and Luzi, 2004; Basu et al., 1996). Furthermore, the loss of an early insu-
lin response is involved in glucose intolerance in diabetes (Basu et al.,
1996; Calles-Escandon and Robbins, 1987;Mitrakou et al., 1992). There-
fore, the quality of biphasic GSIS control may represent a therapeutic
target for better glycemic regulation in type 2 diabetes (Seino et al.,
2011; Caumo and Luzi, 2004). However, the mechanisms underlying
diabetes-related abnormal biphasic GSIS are not yet fully understood.
Interestingly, fasting also inhibits ﬁrst-phase GSIS (Fink et al., 1974;
Grey et al., 1970). This suggests that fasting-dependent changes in ﬁrst-
phase GSISmay affect glucosemetabolismeven in non-diabetic individ-
uals. Given that glucose distribution is independent of insulin action in
the brain but insulin-dependent in peripheral tissues, such as skeletal
muscle and adipose tissue, changes in ﬁrst-phaseGSISmay inﬂuence di-
etary glucose distribution to tissues during re-feeding. Decreased ﬁrst-
phase GSIS after fasting may accelerate a passive glucose distribution
to thebrain,whereas enhanced ﬁrst-phaseGSIS during frequent feeding
could stimulate glucose uptake and anabolism in insulin-sensitive tis-
sues. This may represent an important physiological role of ﬁrst-phase
GSIS in whole-body glucose homeostasis during re-feeding.
In this study, we hypothesized that biphasic GSIS is an adaptive sys-
tem that appropriately distributes dietary glucose to either the brain or
insulin-sensitive tissues, depending on the last fasting period. Further-
more, we proposed that both diabetes- and fasting-related inhibition
of ﬁrst-phase GSIS are regulated by a common system.We demonstrat-
ed that hypothalamic AMP-activated protein kinase (AMPK) senses
fasting periods and controls ﬁrst-phase GSIS via the sympathetic
nervous system (SNS). Additionally, dysregulation of this system is
involved in β cell dysfunction in type 2 diabetes.
2. Materials and Methods
2.1. Study Approvals
All human study volunteers providedwritten informed consent. The
study protocol was approved by the Scientiﬁc-Ethical Committees of
Shiga University of Medical Science and adhered to the guidelines of
the Declaration of Helsinki regarding ethical principles for medical re-
search involving human subjects. Additionally, all procedures with ani-
mals were performed in accordancewith the guidelines of the Research
Center for Animal Life Science of ShigaUniversity ofMedical Science and
followed the guidelines provided by the Animal Research: Reporting In
Vivo Experiments (ARRIVE) guideline.
2.2. Human 18F-FDG-PET-CT Analysis
Fig. S1A displays a schematic of the protocol for 2-[ﬂuorine-18]-2-
deoxy-D-glucose (18F-FDG) positron emission tomography (PET)-
computed tomography (CT) and intravenous glucose infusion after 3
and 12 h of fasting in three healthy volunteers. We chose 3-h and 12-
h fasts to represent physiologically relevant timeframes from daily life.
These intervals correspond to common intervals between breakfast
and lunch and between dinner and breakfast, respectively. We per-
formed 18F-FDG-PET-CT on the three volunteers after the 3-h and 12-
h fasts. The interval between the two examinations was 2 weeks. For
the 12-h fasting condition, all volunteers were instructed to refrainfrom smoking and drinking coffee or alcoholic beverages from
9:00 pm on the night before the study. For the 3-h fasting condition,
the volunteers received oral glucose (75 g) at 6:00 am and were placed
in a comfortable supine position. The experiments began at 9:00 am.
Glucose (0.3 g/kg) was administered intravenously over 1.5 min,
followed by intravenous injection of 18F-FDG. Sequential scans of the
brain were obtained at 3-min intervals during the ﬁrst 30 min after
the injections. Whole-body scans were obtained 120 min after glucose
and 18F-FDG injections. The standardized uptake value was analyzed
to quantify the accumulated 18F-FDG in the indicated tissues
(Lucignani et al., 2004).
2.3. Human FSIVGTTs
Fig. S1B displays a schematic of the FSIVGTT performed in 40 healthy
volunteers after fasting for 3 or 12 h. The fasting and meal conditions
were the same as those described in Section 2.2. At 9:00 am, fasting
blood samples were collected. We then administered 0.3 g/kg glucose
intravenously over 1.5 min, and blood was collected after 2, 4, 6, 8, 10,
12, 14, 16, 19, 22, 27, 32, 42, 52, 62, 72, 82, 92, 102, 112, and 122 min.
The acute insulin response (AIR) and glucose disappearance rate (Kg)
were evaluated with MINMOD Millennium (Pacini and Bergman,
1986; Boston et al., 2003). Blood glucose, plasma insulin, free fatty
acid, and hemoglobin A1c (NGSP value) concentrations were measured
using standard laboratory methods. The active forms of glucagon-like
peptide 1 and glucose-dependent insulinotropic polypeptideweremea-
sured using cell-based bioassaymethods (Yanagimachi et al., 2016). The
mean values of these parameters as well as clinical characteristics, in-
cluding gender, age, body weight, body mass index, homeostasis
model assessment of insulin resistance, homeostasis model assessment
of beta cell function (HOMA-β), and blood pressure, in the 40 volunteers
are displayed in Table S1.
2.4. Hyperglycemic (HG) Clamping
HG clamping was performed using standard methodology in 12 of
the 40 volunteer subjects who had undergone FSIVGTTs. Plasma insulin
concentrations at 120min after glucose infusion initiationwere deﬁned
as steady-state insulin levels. The clamped glucose level for evaluating
insulin secretory capacity was 200 mg/dL. Time-dependent changes
in mean glucose and insulin concentrations in the 12 subjects are
displayed in Figs. S2A and B.
2.5. Genomic DNA Extraction and Single Nucleotide Polymorphism (SNP)
Genotyping
Genomic DNA sampleswere harvested fromperipheral blood leuko-
cytes from 40 healthy subjects following a standard protocol. Individual
SNP genotypes were analyzed using a multiplex-PCR invader assay
(Ohnishi et al., 2001).We selected SNPs associatedwith insulin secreto-
ry capacity among those associated with diabetes development. These
SNPs are listed in Table S2. The accumulated number of risk alleles for
impaired insulin secretion was deﬁned as genetic risk score (GRS).
2.6. Animal Care
Male Sprague-Dawley (SD), Long-Evans Tokushima Otsuka (LETO),
and Otsuka Long-Evans Tokushima Fatty (OLETF) rats were obtained
from Shimizu Laboratory Supplies (Kyoto, Japan). Experimental rats
were individually housed in a regulated environment (22 ± 2 °C,
55% ± 10% humidity, 12:12 h light/dark cycle with light on at 7 am).
Food andwaterwere available ad libitum except as otherwise indicated.
During long-term fasting experiments up to 72 h, rats were able to free-
ly access drinking water. We monitored their physical condition at 6-h
intervals. Throughout the study, none of the fasted rats displayed
signs of wasting.
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Cannulas were inserted into the cervical veins in the indicated rats
under anesthesia. One week later, glucose (0.35 g/kg body weight)
was intravenously administered to each animal. Blood samples were
collected via the tail vein and/or portal vein via a portal vein cannula
at 0, 1, 2, 4, 6, 8, 10, 15, 20, 30, 60, 90, and 120 min after glucose injec-
tion. Blood glucose concentrations were measured using a Glutest sen-
sor (Sanwa Kagaku, Nagoya, Japan), and plasma insulin concentrations
were determined by ELISA (Morinaga Institute of Biological Science,
Tokyo, Japan).
The AIR was calculated as the area under the curve (AUC) of insulin
concentrations during the ﬁrst 6min after glucose injection. Kg, deﬁned
as the reduction in the percentage of plasma glucose concentration,was
calculated using the formula (45): Kg (%/min) = (0.693/t 1/2 glu-
cose) × 100, where t 1/2 glucose is the plasma half-life of glucose, calcu-
lated from the slope of log-transformed blood glucose concentrations
between 4 and 30min after glucose administration. During this time in-
terval, the decrease in log-transformed glucose concentration was
linear.
2.8. Rat Oral Glucose Tolerance Test (OGTT) and Intraperitoneal Insulin Tol-
erance Test (IPITT) Studies
For OGTTs, rats were fasted for 8 h, followed by oral glucose admin-
istration (2 g/kg bodyweight). Tail vein blood sampleswere collected at
0, 15, 30, 60, 90, and 120 min. Glucose and insulin concentrations were
measured as described above. The early insulin responsewas calculated
as previously described (Δinsulin15 min/Δglucose15 min) (Han et al.,
2009; Yasuhara et al., 2003). For IPITTs, rats were fasted for 8 h followed
by intraperitoneal insulin injection (0.75 IU/kg bodyweight). Blood glu-
cose was measured using tail blood collected at 0, 15, 30, 60, 90, and
120 min after injection.
2.9. Intravenous Infusion of Drugs
Phentolamine (3 mg/kg/h), propranolol (3 mg/kg/h), or both were
intravenously injected through a cervical cannula into 10-week-old
male SD and 32-week-old male OLETF rats following fasting (24-h or
72-h, as indicated). The infusion began 2 h before glucose administra-
tion and continued until the end of the FSIVGTT. Epinephrine (9 μg/
kg/min) and norepinephrine (0.1mg/kg/h)were continuously adminis-
tered to 10-week-old male SD rats beginning 30 min before glucose ad-
ministration and continuing until the end of the FSIVGTT.
2.10. Intracerebroventricular (ICV) Drug Infusion
Nine-week-old male SD and 31-week-old male OLETF rats with
intravenous cannulas underwent stereotactic implantation of a
stainless steel guide cannula (Plastics One, Roanoke, VA) into the
third cerebral ventricle. One week later, glucose (60 mg/h), insulin
(40 mU/h), 2-deoxy-D-glucose (2-DG; 100 μmol), 5-aminoimidazole-
4-carboxamide-1-β-d-ribofuranoside (AICAR; 10 μg), LY294002
(10 nmol), or compound C (10 μg) was infused or injected into the
inserted cannula 30 min before intravenous glucose injection. All sub-
stances were dissolved in artiﬁcial cerebrospinal ﬂuid.
2.11. Pancreatic Denervation (PNx) and Hepatic Vagotomy (HVx) in SD
Rats
Nine-week-old male SD rats with intravenous cannulas underwent
PNx (Buijs et al., 2001) orHVx (Unoet al., 2006) as previously described.
All operations were performed 1 week before the indicated examina-
tions. PNx, HVx, and sham operations were followed by FSIVGTTs after
a 72-h fast.2.12. Effect of PNx on First-Phase GSIS in OLETF Rats
We examined whether PNx could ameliorate the decrease in ﬁrst-
phase GSIS and glucose intolerance in 32-week-old OLETF rats. Thirty-
one-week-old male OLETF rats with intravenous cannulas were ran-
domly assigned to receive either the sham operation or PNx. FSIVGTTs
were performed following a 24-h fast 1 week after the operation.
2.13. Preventive Effect of PNx on Diabetes in OLETF Rats
The aim of this experiment was to investigate whether PNx could
prevent the development of glucose intolerance in OLETF rats. Eight-
week-old male OLETF rats were randomly assigned to receive either
the sham operation or PNx and were followed until 32 weeks of age.
Age-matched LETO rats that underwent a sham-operation were used
as the control group. At the end of the experiment, the three groups of
rats underwent IPITTs and OGTTs and were then sacriﬁced after urine
collection. Tissue samples were ﬁxed with 4% paraformaldehyde in
PBS and embedded in parafﬁn. Plasma samples were stored at−80 °C
until further use.
2.14. Therapeutic Effect of PNx on Diabetes in OLETF Rats
To determine the therapeutic potency of PNx on the established di-
abetic phenotype, 32-week-old male OLETF rats were randomly
assigned to receive either the sham operation or PNx. OGTTs were per-
formed 3 weeks after the operation. Blood glucose levels in the rats
were thenmonitored everyweek until 76weeks of age to assesswheth-
er they developed severe hyperglycemia, deﬁned as a blood glucose
level ≥ 400 mg/dL. The data were statistically analyzed using the
Kaplan-Meier method and compared using log-rank tests.
Three of the sham-operatedOLETF rats that developed severe hyper-
glycemia underwent PNx at 76weeks of age. OGTTswere performed be-
fore and after surgery to investigate whether PNx can improve the
severe diabetic phenotype observed in 76-week-old OLETF rats.
2.15. Histological Analysis
Fixed tissues were embedded in parafﬁn and sectioned. Kidney sec-
tionswere stained with PAS, and liver andwhite adipose tissue sections
were stained with hematoxylin and eosin. Pancreatic sections were
stained with antibodies against insulin (1:500, Abcam, #ab7842) and
glucagon (1:100, Sigma-Aldrich, #G2654). TUNEL staining was per-
formed in accordance with the manufacturer's instructions (TaKaRa,
#MK500). Immunoﬂuorescent staining of the hypothalamus was per-
formed with an anti-phosphorylated AMPKThr172 antibody (1:50, Cell
Signaling Technology, #2531). The rat ventromedial hypothalamic
nucleus (VMH) was sectioned 2.56 mm posterior to the bregma,
±0.4 mm laterally and 9.5 mm from the dural surface (Satoh et al.,
1997). Podocyte structure was evaluated by scanning electron
microscopy (Hitachi S-570, Tokyo, Japan). To analyze the β cell area in
pancreatic sections, the proportion of the insulin-positive area in the
total pancreatic area was evaluated in each insulin-stained section
using ImageJ software. Seven pancreatic sections were analyzed in
each animal. The apoptotic index was calculated as a percentage of
TUNEL-positive cells using the following formula: apoptotic index =
100 × (number of TUNEL-positive cells / number of insulin-positive
cells).
2.16. Electrophoresis of Urine Samples
Collected urine sampleswere boiled in sodiumdodecyl sulfate (SDS)
sample buffer and subjected to SDS-PAGE. Gelswere visualized by stain-
ing with Coomassie Brilliant Blue.
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Rat hypothalamus samples were homogenized in an ice-cold lysis
buffer containing 150 mmol/l NaCl, 50 mmol/l Tris-HCl (pH 8.0), 0.1%
SDS, 1% Nonidet P-40, a PhosSTOP Phosphatase Inhibitor Cocktail
(Rosche, Osaka, Iapan) and protease inhibitor cocktail (Boehringer
Mannheim, Lewes, UK). These samples were resolved by 10% SDS-poly-
acrylamide gel electrophoresis and transferred to polyvinylidene ﬂuo-
ride membranes (Immobilon, Bedford, MA). The membranes were
incubated with anti-β actin antibody (Sigma, Tokyo, Japan, #A5316),
anti-phospho-acetyl CoA carboxylase (ACC) (Ser79) antibody (Upstate
Cell Signaling, Lake Placid, NY, #07–303), anti-AMPK, anti-phospho
AMPK (Thr172) and anti-ACC antibodies, (Cell Signaling Technology,
Beverly,MA, #4150, #2531, and#3662 respectively), washed, and incu-
bated with horseradish peroxidase-coupled secondary antibodies
(Amersham, Buckinghamshire, UK). The blots were visualized using
an enhanced chemiluminescence detection system (Perkin Elmer Life
Science, Boston, MA).2.18. Statistics
Values are expressed as the means ± SEM. In the human study,
Student's t-test was used for statistical analysis of each parameter
after normality was conﬁrmed. Associations between parameters wereFig. 1. Fasting increases brain glucose distribution in human subjects during an FSIVGTT. (A–C)
12-h and 3-h fasts in three independent subjects. The standardized uptake value (SUV) obtained
and 3-h fasts in three independent subjects. (D–F)Whole-body analysis of 18F-FDG-PET-CT at 1
the indicated tissues. Graphs display mean ± SEM. Statistical signiﬁcance was calculated us
[ﬂuorine-18]-2-deoxy-D-glucose positron emission tomography-computed tomography; FSIVGanalyzed with Pearson's correlation coefﬁcient. For the animal studies,
we performed Wilcoxon-Mann-Whitney tests and Kruskal-Wallis tests
followed by post hoc Bonferroni analysis for comparison between two
groups and among multiple groups, respectively. Survival parameters
were determined using the Kaplan-Meier method and compared
using log-rank tests. In all analyses, a P-value b 0.05 was deﬁned as
statistically signiﬁcant.3. Results
3.1. Effect of Fasting on Tissue Glucose Uptake after Glucose Injection in
Healthy Human Subjects
We ﬁrst exploredwhether fasting time affected whole-body glucose
distribution. Brain images obtained during the ﬁrst 30 min of intrave-
nous co-injections of glucose and 18F-FDG revealed more rapid 18F-
FDG uptake by the brain after a 12-h fast compared with that following
a 3-h fast (Fig. 1A–C andMovie S1A–C).Whole-body images at 120min
indicated thatmost of the 18F-FDG accumulated in the brain after a 12-h
fast, whereas skeletalmuscles displayed the greatest accumulation after
a 3-h fast (Fig. 1D–F andMovie S1A–C). The effect of fasting time on 18F-
FDG deposition in other tissues varied among individual subjects
(Fig. 1D–F and Movie S1A–C). These results suggest that fasting period
length can affect whole-body glucose distribution during re-feeding.Sequential 18F-FDG-PET-CT images of the brain during the ﬁrst 30 min of an FSIVGTT after
from 18F-FDG-PET-CT images of the brain during the ﬁrst 30min of an FSIVGTT after 12-h
20min post-glucose administration in three independent subjects. Analysis of the SUVs in
ing paired Student's t-test. P b 0.05 indicates statistical signiﬁcance. 18F-FDG-PET-CT, 2-
TT, frequently sampled intravenous glucose tolerance test.
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Wenext investigated the possible involvement of ﬁrst-phase GSIS in
the fasting-dependent increase in glucose uptake in to the brain. Kg and
AIR were signiﬁcantly lower after a 12-h fast compared with those
following a 3-h fast (Fig. 2A and B). Insulin sensitivity was similar
(Fig. S2C). This phenomenon was observed in all subjects, although
the rates of reduction varied among individuals (Fig. S2D). Therefore,
the fasting-dependent reduction in ﬁrst-phase GSIS and the subsequent
Kg might be involved in a greater increase in passive brain glucose up-
take in human subjects after longer fasting periods.
The relationship between glucose and insulin concentrations during
the FSIVGTT was approximately linear (Fig. 2C), with similar x-inter-
cepts regardless of the fasting time (Fig. 2C and D). However, the
X-coefﬁcient was signiﬁcantly lower after the 12-h fast compared
with that following the 3-h fast (Fig. 2C and E), suggesting that differ-
ences in fasting duration affected the responsiveness of GSIS to changesFig. 2. Fasting decreases ﬁrst-phase GSIS in human subjects. (A and B) Blood glucose changes a
fasts (n = 40). (C) Glucose-insulin regression curves calculated from the results from FSIVGTTs
(E) of the individual glucose-insulin lines (n = 40). (F and G) Plots (F) and proportional distr
curves for 3-h and 12-h fasted FSIVGTTs in 40 individuals. (H and I) Correlations of the esti
FSIVGTT with insulin concentrations during HG clamps (n = 12). (J and K) Correlation curve
during an FSIVGTT with HOMA-β (n = 40). Statistical signiﬁcance was calculated using a p
statistical signiﬁcance; r indicates Pearson's rank correlation coefﬁcient. GSIS, glucose-stim
FSIVGTT, frequently sampled intravenous glucose tolerance test; HG clamp, hyperglycemic clain glucose levels. Fasting duration had no effect on the threshold glucose
level required to enhance insulin secretion.
3.3. Clinical Signiﬁcance of the Fasting-Dependent Decrease in First-Phase
GSIS
The clinical signiﬁcance of the 3-h and 12-h fasting FSIVGTT results
was assessed in 12 of the 40 healthy subjects by comparing the results
of these protocols with those of a HG (200 mg/dL) clamp technique
(Fig. S2A and B)—a reliable method for evaluating insulin secretory ca-
pacity (DeFronzo et al., 1979). Using the glucose-insulin regression
lines from FSIVGTTs conducted after 12-h and 3-h fasts, insulin levels
were estimated at blood glucose levels of 200 mg/dL. We conﬁrmed
that the estimated insulin levels from FSIVGTTs after a 3-h fast were sig-
niﬁcantly higher than those obtained after a 12-h fast, similar to the AIR
results (Fig. 2F and G). Furthermore, estimated insulin levels after a 3-h
fast exhibited a stronger correlation with steady-state insulin levels de-
termined using the HG clamp method when compared with resultsnd Kg (A) and plasma insulin changes and AIRs (B) during an FSIVGTT after 12-h and 3-h
after 12-h and 3-h fasts (n = 40). (D and E) Plots of the X-intercept (D) and X-coefﬁcient
ibution (G) of the estimated insulin values calculated from the glucose-insulin regression
mated insulin concentrations at a blood glucose concentration of 200 mg/dL during an
s of the estimated insulin concentrations at a blood glucose concentration of 200 mg/dL
aired Student's t-test. The horizontal bars represent the mean values. P b 0.05 indicates
ulated insulin secretion; Kg, glucose disappearance rate; AIR, acute insulin response;
mp; HOMA-β, homeostasis model assessment beta-cell function index.
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estimated insulin concentrations obtained from FSIVGTTs after a 3-h
fast displayed stronger positive correlations with HOMA-β than those
obtained after a 12-h fast (Fig. 2J and K).
To further demonstrate that a 3-h fast is superior for determining in-
sulin secretory capacity during an IVGTT than a 12-h fast, we performed
a correlation analysis between GRS associated with lower insulin secre-
tory capacity and IVGTTs after different fasting periods using samples
from all 40 volunteers. Both the AIRs and the estimated insulin levels
obtained from 3-h fasted FSIVGTTs were inversely and more strongly
correlated with the GRS, than those from 12-f fasted FSIVGTTs
(Table 1). Collectively, an FSIVGTT after a 3-h fast may better determine
insulin secretory capacity than that measured after the 12-h fast com-
monly employed in clinical settings.3.4. Effect of Fasting on First-Phase GSIS in Non-Diabetic Rats
In our human study, ﬁrst-phase GSIS was diminished after a 12-h
fast, suggesting that a longer fasting time may more strongly inhibit
ﬁrst-phase GSIS. Furthermore, the enhanced ﬁrst-phase GSIS observed
following a 3-h fastmight be because of secondary effects of oral glucose
ingestion rather than prior elevation of blood glucose levels. We ad-
dressed these issues by conducting double FSIVGTTs after longer fasting
periods in rats.
The ﬁrst FSIVGTT following a 72-h fast signiﬁcantly inhibited ﬁrst-
phase GSIS with decreased Kg and led to the appearance of second-
phase GSIS (Fig. 3A–D). In contrast, ﬁrst-phase GSIS during the second
FSIVGTT, which was conducted 2-h after the ﬁrst FSIVGTT, was recov-
ered even in a 72-fast FSIVGTT (Fig. 3C–D). These results reveal that
shorter fasting times enhanced ﬁrst-phase GSIS similar to our human
study, and that extended fasting more strongly inhibited ﬁrst-phase
GSIS. Furthermore, ﬁrst-phase GSIS was regulated by prior glucose
exposure, regardless of intravenous or oral administration.
Fasting-induced reductions in Kg and ﬁrst-phase GSIS were ob-
served in blood samples from both the tail and portal veins of rats
(Fig. 3E–G), indicating that hepatic insulin degradation was not in-
volved in the fasting-induced suppression of ﬁrst-phase GSIS. Further-
more, the fasting-induced decreases in Kg and early-phase insulin
secretion were conﬁrmed using OGTTs (Fig. 3H–K), suggesting that
the fasting-dependent decrease in ﬁrst-phase GSIS occurred regardless
of whether glucose was administered intravenously or orally.Table 1
Regression analysis between the genetic risk score for type 2 diabetes mellitus and the in-
sulin secretion parameters evaluated by the 3-h and 12-h fasting IVGTTs.
Acute insulin response (AIR) Estimated insulin levels at
200 mg/dl glucose
12-h fast 3-h fast 12-h fast 3-h fast
Unadjusted model r = −0.313 r = −0.369 r = −0.273 r = −0.472
p = 0.050 p = 0.019 p = 0.089 p = 0.002
Adjusted model r = −0.472 r = −0.490 r = −0.442 r = −0.513
p = 0.003 p = 0.002 p = 0.006 p = 0.001
The genetic risk score (GRS) was determined using the cumulative number of risk alleles
in each single nucleotide polymorphisms (SNPs). The SNPs used for the correlation analy-
sis of the genetic risk score are listed in the Table S2. The acute insulin response (AIR) in
the intravenous glucose tolerance test (IVGTT) was calculated with the MINMOD Millen-
nium software. The estimated insulin level at 200 mg/dl of blood glucose was calculated
from the glucose-insulin regression curve from the 3-h and 12-h fasting IVGTTs. The cor-
relations between the GRS and each insulin secretion parameter were analyzed with an
unadjusted model (upper) and a model adjusted by the body mass index and age
(lower). r indicates Pearson's rank correlation coefﬁcient. The P value indicates the signif-
icance of the correlation between the indicated parameters. P b 0.05 indicates statistical
signiﬁcance.3.5. Role of the Brain-SNS-β Cell Neural Axis in First-Phase GSIS in Non-
Diabetic Rats
Because the hypothalamus-SNS axis plays a fundamental role in
whole-body glucose homeostasis during fasting (Myers and Olson,
2012; Kurose et al., 1990), we next examined the role of the SNS in reg-
ulating ﬁrst-phase GSIS. Continuous infusion of the catecholamines epi-
nephrine and norepinephrine signiﬁcantly reduced ﬁrst-phase, but
increased second-phase, GSIS—even when FSIVGTTs were performed
after a 24-h fast (Fig. S3A–D). Infusion of the α-blocker phentolamine
or the β-blocker propranolol did not affect Kg during FSIVGTTs after a
72-h fast, whereas co-infusion of both blockers signiﬁcantly increased
Kg (Fig. S3E and F). First-phase GSIS was signiﬁcantly potentiated by
phentolamine—even after a 72-h fast—but reduced slightly by propran-
olol (Fig. S3G and H). Furthermore, PNx signiﬁcantly increased ﬁrst-
phase GSIS and Kg, even during an FSIVGTT after a 72-h fast (Fig. 4A–
D). Therefore,α-adrenergic SNS signaling is involved in themechanism
underlying fasting-induced inhibition of ﬁrst-phase GSIS.
3.6. Role of Hypothalamic AMPK in First-Phase GSIS in Non-Diabetic Rats
The liver senses peripheral glucose metabolism and communicates
this information to the brain via the hepatic vagal nerve (Uno et al.,
2006). Additionally, the hypothalamus directly senses a quick change
in nutrient conditions via the insulin signaling or glucose-sensing path-
ways (Minokoshi et al., 2004). We found that hepatic vagotomy had no
effect on ﬁrst-phase GSIS, although it increased Kg, during FSIVGTTs
following a 72-h fast (Fig. S3I–L). In contrast, ICV injections of glucose,
but not insulin, signiﬁcantly increased both Kg and ﬁrst-phase
GSIS during FSIVGTTs following a 72-h fast (Fig. 4E–H). ICV injections
of 2-DG, a nonmetabolizable glucose analog, but not LY294002, a phos-
phatidylinositol 3-kinase inhibitor, signiﬁcantly decreased Kg and ﬁrst-
phase GSIS, even in FSIVGTTs following a 24-h fast (Fig. 4I–L). These
results suggest that the glucose-sensing pathways in the brain are
essential for regulating ﬁrst-phase GSIS.
AMPK is an intracellular effector that signals in response to glucose
utilization, glycogen content, and leptin (Kahn et al., 2005; Long and
Zierath, 2006). Hypothalamic AMPK regulates glucose and energy me-
tabolism (Long and Zierath, 2006; Minokoshi et al., 2004; Lopez et al.,
2010; Xue and Kahn, 2006; McCrimmon et al., 2008). Particularly,
AMPK in the VMH is involved in the physiological responses to fasting,
such as gluconeogenesis and inhibition of glucose utilization in periph-
eral tissues(Lopez et al., 2010; McCrimmon et al., 2008). We conﬁrmed
that phosphorylation of AMPK and ACC, a direct substrate of AMPK, in
the VMH signiﬁcantly increased depending on fasting duration but
was abolished by ICV glucose infusions (Fig. 4M–P). In contrast, ICV 2-
DG infusions activated AMPK, even following a 24-h fast (Fig. 4M–P).
ICV injections of AICAR, an AMPK activator, signiﬁcantly reduced Kg
and ﬁrst-phase GSIS, even during an FSIVGTT following a 24-h fast
(Fig. 4I–L). Moreover, ICV AICAR injections reduced the effects of ICV
glucose injection on Kg and GSIS during an FSIVGTT following a 72-h
fast (Fig. 4E–H). Taken together, these ﬁndings indicate that the activa-
tion of hypothalamic AMPK, which senses brain glucose depletion, in-
hibits ﬁrst-phase GSIS.
3.7. Role of the Brain-β Cell Neural Axis in the Impairment of First-Phase
GSIS in Diabetic Rats
We investigated the relationship between fasting- and diabetes-
induced suppression of ﬁrst-phase GSIS. When compared with non-
obese control LETO rats, OLETF rats displayed a normal Kg during an
FSIVGTT following a 24-h fast until 24 weeks of age. However, Kg was
signiﬁcantly reduced in OLETF rats at 32 weeks of age (Fig. 5A and B).
First-phase GSIS was signiﬁcantly increased in 16-week-old OLETF
rats. In contrast, ﬁrst-phase GSIS was lower, while second-phase GSIS
was higher, in 32-week-old OLETF rats (Fig. 5C and D). A similar pattern
Fig. 3. Fasting decreases ﬁrst-phase GSIS in non-diabetic rats. (A–D) Blood glucose concentrations (A), Kg (B), insulin levels (C), and insulin AUC0–6 min (D) during the dual FSIVGTT in rats
fasted for 24 h (n= 5), 48 h (n= 7), and 72 h (n= 7). (E and F) Blood glucose (E) and plasma insulin (F) levels in blood obtained from the tail and portal veins during the FSIVGTT. (G)
Insulin AUC0–6 min in the tail and portal veins during the FSIVGTT (n = 5 each). (H–K) Blood glucose concentrations (H), glucose concentrations at 2 h post-glucose injection (I), insulin
levels (J), and Δinsulin15 min/Δglucose15 min (K) in healthy rats that had been fasted for 24 or 72 h (n= 4 each). Statistical signiﬁcance was calculated using theWilcoxon-Mann-Whitney
test or the KruskalWallis test followed by Bonferroni's post-hoc test for comparisons between two groups or amongmultiple groups, respectively. P b 0.05 indicates statistical signiﬁcance.
N.S. indicates no statistical signiﬁcance. Graphs display mean ± SEM. GSIS, glucose-stimulated insulin secretion; Kg, glucose disappearance rate; AUC, area under the curve; FSIVGTT,
frequently sampled intravenous glucose tolerance test.
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fast (Fig. 3C andD). The pancreaticβ cell areas of OLETF ratswere signif-
icantly larger than those of age-matched control LETO rats, regardless of
age (Fig. 5E and F), although the pancreas appeared to be of equivalent
weight among the groups of rats. These results suggested that diabetes-
related inhibition of ﬁrst-phase GSIS in 32-week-old OLETF rats was not
mediated by insufﬁcient β-cell insulin production.
Systemic co-infusion of α- and β-blockers (Fig. S3E–H) or PNx
(Fig. 5G–J) reversed the diabetes-induced reductions in ﬁrst-phase GSIS
and Kg in 32-week-old OLETF rats during an FSIVGTT following a 24-h
fast. We demonstrated that phosphorylation of AMPK and ACC signiﬁ-
cantly increased in hypothalamus of these 32-week-old OLETF rats (Fig.
5K–N), even though they were not subjected to a 72-h fast. Furthermore,
this activationwas abolished by ICV injection of the AMPK inhibitor com-
pound C (Fig. 5K–N), which also ameliorated ﬁrst-phase GSIS (Fig. 5O–R).
Collectively, these results indicate that the brain-β cell neural axis is also
involved in the diabetes-related decrease in ﬁrst-phase GSIS.Fig. 4. Hypothalamic AMPK-SNS axis control of ﬁrst-phase GSIS during fasting. (A–D) Blood g
FSIVGTT in rats fasted for 72 h with or without PNx (n = 5 each). (E–H) Blood glucose levels
rats fasted for 72 h and pre-injected ICV with control aCSF containing urea (n = 7), glucose (
(J), plasma insulin levels (K), and insulin AUC0–6 min (L) during FSIVGTTs in rats fasted for 24
AICAR (n = 8). (M) Immunoﬂuorescent labeling of phosphorylated AMPK in the hypothalam
in the hypothalamus of indicated rat groups. β-actin was used as a control. (O) Quantitative re
signiﬁcance was calculated using a Wilcoxon-Mann-Whitney test or a Kruskal Wallis test
multiple groups, respectively. P b 0.05 indicates statistical signiﬁcance. N.S. indicates no statist
activated protein kinase; SNS, sympathetic nervous system; GSIS, glucose-stimulated ins
intravenous glucose tolerance test; PNx, pancreatic denervation; aCSF, artiﬁcial cerebrospin
ribofuranoside; 2-DG. 2-deoxy-D-glucose.3.8. Therapeutic Potency of Pancreatic Denervation against Type 2 Diabetes
Among the strategies that restore ﬁrst-phase GSIS inOLETF rats, only
PNx plays a direct role in β cell dysfunction without affecting glucose
metabolism in other peripheral tissues. Thus, 8-week-old OLETF rats
were subjected to PNx, and followed until 32week-old to assess the sig-
niﬁcance of restoredﬁrst-phase GSIS on diabetes onset (Fig. 6A). A com-
parison of sham- and PNx-treated OLETF rats revealed no differences in
dietary intake, body weight gain, or fasting fatty acid, triglyceride, and
total cholesterol levels (Table S3). Furthermore, PNx did not affect insu-
lin resistance in OLETF rats following an IPITT (Fig. 6B). However, PNx in
OLETF rats signiﬁcantly improved glucose tolerance, accompanied by an
amelioration of early-phase insulin secretion during an OGTT (Fig. 6C–
F). The pancreas appeared to be similar weight among three groups of
rats. Furthermore, PNx did not affect enlargement of β cell areas in the
pancreas or lipid accumulation in the liver and white adipose tissues
in OLETF rats (Fig. 6G–I). Thus, PNx played a preventive role in thelucose levels (A), Kg (B), plasma insulin levels (C), and insulin AUC0–6 min (D) during the
(E), Kg (F), plasma insulin levels (G), and insulin AUC0–6 min (H) during the FSIVGTT in
n = 6), insulin (n = 5), or glucose and AICAR (n = 6). (I–L) Blood glucose levels (I), Kg
h and pre-injected ICV with control aCSF (n = 10), 2-DG (n = 5), LY294002 (n = 5), or
us. Scale bar, 200 μm. (N) Representative Western blots of pACC, ACC, pAMPK and AMPK
sults of the pAMPK/AMPK ratio. (P) Quantitative results of the pACC/ACC ratio. Statistical
followed by Bonferroni's post-hoc test for comparisons between two groups or among
ical signiﬁcance. Graphs display mean ± SEM. ACC, acetyl CoA carboxylase; AMPK, AMP-
ulin secretion; Kg, glucose disappearance rate; AUC, area under the curve; FSIVGTT,
al ﬂuid; ICV, intracerebroventricular; AICAR, 5-aminoimidazole-4-carboxamide-1-β-d-
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related morphological changes in various tissues.
Increased urinary protein excretion levels, glomerular sclerotic
lesions, and severe alterations of podocyte foot processes, all of which
are relevant to diabetic nephropathy, were observed in the kidneys
of 32-week-old sham-treated OLETF rats and prevented by PNx(Fig. 6J–L). These renoprotective effects of PNx provide evidence that
PNx chronically improved glycemic control in OLETF rats.
We also assessed the therapeutic effectiveness of PNx on type 2 dia-
betes (Fig. 7A). PNx signiﬁcantly improved glucose tolerance and in-
creased the early insulin secretory response following an OGTT in 32-
week-old OLETF rats (Fig. 7B–E). As OLETF rats develop age-dependent
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we assessed the effects of PNx on the age-dependent progression of se-
vere hyperglycemia deﬁned as a blood glucose level ≥ 400 mg/dL until
76-week old (Fig. 7A). Six of the 10 sham-treated OLETF rats developed
severe hyperglycemia, whereas signiﬁcantly fewer PNx-OLETF rats ex-
hibited this progression (Fig. 7F). Moreover, fewer TUNEL-positive
cells were present in the islets of 76-week-old PNx rats compared
with those of 76-week-old sham-treated OLETF rats (Fig. 7G and H).
However, PNx failed to reverse the diminished ﬁrst-phase GSIS ob-
served in 76-week-old OLETF rats that had developed severe hypergly-
cemia (Fig. 7I–K). Collectively, these results indicate that PNx can delay
the onset of glucose intolerance, improve glycemic control in the early
stages of diabetes andprevent the loss ofβ cellmass during the progres-
sion of severe diabetes. However, PNx is unable to restore insulin secre-
tion once the β cell mass is mostly depleted, as in end-stage diabetes.
4. Discussion
The present study demonstrated a physiological role of ﬁrst-phase
GSIS. Our study revealed that biphasic GSIS regulated the distribution
of adequate amounts of glucose to tissues at re-feeding, and the rate
of distribution depended on the duration of the previous fasting period.
First-phase GSIS is decreased after long-term fasting but is fully induced
in the unfasted state (Fig. 8). This system results in the brain being sup-
plied with glucose as soon as possible after a fast, while also facilitating
effective storage of surplus energy in insulin-sensitive tissues to prepare
for upcoming fasting periods (Fig. 8). Although blood glucose levels are
strictly regulated within a narrow range, postprandial blood glucose
levels may require additional ﬁne-tuning by ﬁrst-phase GSIS to supply
an adequate amount of dietary glucose to the brain in response to the
most-recent fasting period.
A long fasting period of 72 h dramatically inhibited ﬁrst-phase GSIS
in our animal study, suggesting that the fasting-dependent decrease in
ﬁrst-phase GSIS might be more important for mammals living in times
of scarcity than for humans living in our current time of relative plenty.
Insulin halts most catabolic processes, including glycogenolysis, gluco-
neogenesis, and ketogenesis—all of which are essential for maintaining
anenergy supply to thebrain during a prolonged fast, such as starvation.
Therefore, if ﬁrst-phase GSIS is not suppressed at re-feeding after star-
vation, insulin action on peripheral tissues may cause an inadequate re-
duction in postprandial blood glucose levels by inhibiting catabolic
processes and enhancing glucose utilization by peripheral tissues. This
may result in the brain being supplied with insufﬁcient energy. There-
fore, ﬁrst-phase GSIS may have to be suppressed after starvation. A def-
icit in ﬁrst-phase GSIS may therefore be a common insulin secretion
pattern during scarce times, whereas increased ﬁrst-phase GSIS is rec-
ognized as a normal pattern during times of plenty.
The mechanism by which ﬁrst-phase GSIS is reduced after fasting is
related to the mechanism underlying diabetes-associated ﬁrst-phase
GSIS impairment. Although the impaired ﬁrst-phase GSIS observed in
diabetes has long been thought to be a loss-of-function of insulin secre-
tion (Weyer et al., 1999), a gain-of-function of fasting-induced suppres-
sion of ﬁrst-phase GSIS may actually be responsible. The activation of
the brain-SNS-β cell neural axis is a ﬁnal common pathway that inhibits
ﬁrst-phase GSIS, regardless of blood glucose levels. During fasting, the
axis is physiologically activated to maintain postprandial glucose levels.
Under diabetic conditions, the neural axis is pathologically activated,
leading to inhibition of ﬁrst-phase GSIS, because hypothalamic AMPK
is abnormally activated despite the existence of hyperglycemia. These
ﬁndings suggest that β cells during early type 2 diabetesmaymistaken-
ly perceive the diabetic condition as prolonged fasting because of abnor-
mal excitability of the brain-SNS-β cell neural axis.
Hypothalamic AMPK is both a central regulator of glucose homeo-
stasis during fasting and a pathogenic factor that promotes insulin resis-
tance (Kahn et al., 2005; Lopez et al., 2010; Minokoshi et al., 2004; Park
et al., 2014; Kim et al., 2004; McCrimmon et al., 2008). HypothalamicAMPK activation increases appetite, promotes gluconeogenic hormone
secretion, stimulates hepatic gluconeogenesis, and suppresses peripher-
al glucose utilization (Fig. S5). In addition to these properties, we have
demonstrated that crosstalk between hypothalamic AMPK and β cells
regulated ﬁrst-phase GSIS. This ﬁnding provides additional evidence of
the involvement of hypothalamic AMPK in both glucose homeostasis
during fasting and the pathogenesis of type 2 diabetes. During fasting,
AMPK speciﬁcally in the VMH is essential for glucagon- and epineph-
rine-stimulated gluconeogenesis in response to acute hypoglycemia.
Furthermore, it is a negative regulator of glucose uptake and thermo-
genesis in brown adipose tissue (McCrimmon et al., 2008; Lopez et al.,
2010). Thus, we analyzed AMPK activity in the VMH. However, AMPK
in other hypothalamic nuclei might also be involved in the fasting-
dependent decrease in ﬁrst-phase GSIS.
Although α-adrenergic stimulation inhibits insulin secretion from β
cells (Kurose et al., 1990; Skoglund et al., 1988), the physiological
signiﬁcance of this is unknown. Our results indicate that α-adrenergic
pancreatic nerves may speciﬁcally regulate ﬁrst-phase rather than sec-
ond-phase GSIS. Interestingly, ﬁrst-phase GSIS in rats was increased
by α-blocker administration and decreased by β-blocker treatment.
However, neitherα- nor β-blocker treatment altered Kg in the FSIVGTT
studies. In contrast, simultaneous treatment with both blockers
increased Kg and enhanced ﬁrst-phase GSIS, even in fasted rats. These
results suggest that insulin resistance, alongside a deﬁcit in ﬁrst-
phase GSIS, is also involved in the fasting-induced Kg decrease. Thus,
theα- and β-adrenergic nerve systemsmay play opposite roles in insu-
lin secretion and resistance during the re-feeding period to maintain
postprandial glucose levels. Impairment of one system alone does not
induce postprandial hypoglycemia after starvation, because the other
can compensate. This may be the reason why whole body glucose me-
tabolism is regulated by two different sympathetic nerve systems.
The sympathetic regulation of GSIS should be revisited as a
therapeutic target for type 2 diabetes (Porte, 1969). Consistently, we ob-
served that a PNx-induced increase inﬁrst-phaseGSIS improved glycemic
control in diabetic rats. More importantly, this surgical approach
preventedβ cell loss and severe hyperglycemia during late stage diabetes.
The effects of PNxmight result from reduced glucose toxicity (Rossetti et
al., 1990). Furthermore, PNxmight affectβ cell death directly bymodulat-
ing intracellular metabolism or by inhibiting islet inﬂammation via sym-
pathetic immune modulation (Pereira and Leite, 2016). Although the
mechanism remains unclear, our results suggest a concept for future dia-
betic therapy and indicate the need for further study of the mechanisms
that control both the quality and quantity of insulin secretion. Determina-
tion of thesemechanismsmay reveal targets for additional approaches to
diabetes treatment. Additionally, currently approved surgical interven-
tions in internal medicine include bariatric surgery for obesity
(Buchwald et al., 2004; Mingrone et al., 2012) and renal denervation for
hypertension (Esler et al., 2010). Furthermore, early interventions in dia-
betes can improve β cell survival and patient prognosis (Weng et al.,
2008;Holmanet al., 2008). Therefore, PNxmay represent an effective sur-
gical approach for patients with newly diagnosed type 2 diabetes.
Our observations fromhuman FSIVGTT studies that employed differ-
ent fasting periods may explain some outstanding clinical questions,
such as the mechanism underlying the second-meal effect. Further-
more, the poor correlation between the AIR during an FSIVGTT and in-
sulin concentrations determined by HG clamp or HOMA-β methods
has been considered problematic in determining the ability of the
FSIVGTT to estimate an individual's insulin secretory capacity
(Hermans et al., 1999). Our results suggest that the fasting-induced
reduction in the AIR may affect the determination of insulin secretory
capacity using FSIVGTTs. Our present ﬁndings from human FSIVGTT
data indicate that short-term fasting may resolve the technical prob-
lems associated with conventional FSIVGTTs.
The principal aim of this study was to identify a β cell-speciﬁc
change in response to fasting that affected ﬁrst-phase GSIS. Thus, we
performed IVGTTs rather than OGTTs to exclude incretin or decretin
Fig. 5. Hypothalamic AMPK-SNS axis impairment of ﬁrst-phase GSIS in diabetic OLETF rats. (A–D) Blood glucose levels (A), Kg (B), plasma insulin levels (C), and insulin AUC0–6 min
(D) during FSIVGTTs in 16-, 24- and 32-week-old LETO (n = 5, 4, and 5 per group, respectively) and OLETF (n = 4, 4, and 6 per group, respectively) rats after a 24 h fast.
(E) Immunoﬂuorescent staining of insulin and glucagon in pancreatic islets. Scale bar, 100 μm. (F) The proportion of the β cell area in the total pancreatic area. (G–J) Blood glucose
levels (G), Kg (H), plasma insulin levels (I), and insulin AUC0–6 min (J) during FSIVGTTs in 32-week-old OLETF rats treated with (n = 5) or without (n = 7) PNx and fasted for 24 h.
(K) Immunoﬂuorescent labeling of phosphorylated AMPKThr172 in the hypothalamus. Scale bar, 200 μm. (L) Representative Western blots of pACC, ACC, pAMPK and AMPK in the
hypothalamus of indicated rat groups. β-actin was used as a control. (M) Quantitative results of the pAMPK/AMPK ratio. (N) Quantitative results of the pACC/ACC ratio. (O–R) Blood
glucose levels (O), Kg (P), plasma insulin levels (Q), and insulin AUC0–6 min (R) during FSIVGTTs in rats pre-injected ICV with control aCSF containing urea (n = 5) or compound C
(n = 6). Statistical signiﬁcance was calculated using a Wilcoxon-Mann-Whitney test or a Kruskal Wallis test followed by Bonferroni's post-hoc test for comparisons between two
groups or among multiple groups, respectively. P b 0.05 indicates statistical signiﬁcance. N.S. indicates no statistical signiﬁcance. Graphs display mean ± SEM. ACC, acetyl CoA
carboxylase; AMPK, AMP-activated protein kinase; SNS, sympathetic nervous system; GSIS, glucose-stimulated insulin secretion; Kg, glucose disappearance rate; AUC, area under the
curve; FSIVGTT, frequently sampled intravenous glucose tolerance test; PNx, pancreatic denervation; aCSF, artiﬁcial cerebrospinal ﬂuid; ICV intra-third cerebroventricular.
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was involved in the fasting- and diabetes-dependent decrease in ﬁrst-
phase GSIS, and demonstrated therapeutic potency of the brain-insular
axis, in addition to the enteroinsular axis including incretin and decretin
(Drucker and Nauck, 2006; Alfa et al., 2015). However, in vivo, the twoaxes should coordinately regulate ﬁrst-phase GSIS in response to a prior
fasting period. Thus, revealing an interaction between the two axesmay
be an important subsequent research topic.
Our study highlighted several questions that remain unresolved.
First, whether the mechanism by which hypothalamic AMPK is
Fig. 6. Preventive role of pancreatic denervation in the development of type 2 diabetes in OLETF rats. (A) Eight-week-old OLETF rats underwent PNx or sham surgery andweremonitored
until 32 weeks of age. (B) Percent change in glucose levels during the IPITT in non-diabetic LETO (n = 5) and OLETF rats with (n= 6) or without (n = 7) PNx. (C and D) Blood glucose
levels during the OGTT (C) and glucose concentrations at 2 h post-glucose injection during the OGTT (D). (E and F) Plasma insulin levels during the OGTT (E) and the Δinsulin15 min/
Δglucose15 min during the OGTT (F). (G) Immunoﬂuorescent staining of insulin and glucagon in pancreatic islets. Scale bar, 100 μm. (H) The proportion of the β cell area in the total
pancreatic area. (I) Hematoxylin-eosin-stained sections of the liver and white adipose tissue. Scale bar, 100 μm. (J) Coomassie brilliant blue (CBB)-stained albumin bands in urine
samples and control bovine serum albumin (BSA) at the indicated concentrations. (K) Periodic acid-Schiff (PAS)-stained kidney sections. Scale bar, 100 μm. (L) Scanning electron
microscopy (EM) showing podocytes. Magniﬁcation ×8000 and ×30,000. Statistical signiﬁcance was calculated using a Wilcoxon-Mann-Whitney test or Kruskal Wallis test followed
by Bonferroni's post-hoc test for comparisons between two groups or among multiple groups, respectively. P b 0.05 indicates statistical signiﬁcance. N.S. indicates no statistical
signiﬁcance. Graphs display mean ± SEM. IPITT, intraperitoneal insulin tolerance test; PNx, pancreatic denervation; OGTT, oral glucose tolerance test.
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though our ﬁndings are consistent with previous studies (de Andrade
et al., 2015; Kim et al., 2004; Namkoong et al., 2005), no reports haveFig. 7. Therapeutic role of pancreatic denervation in the development of type 2 diabetes in OLE
were analyzed at 36weeks of age, andweremonitored until 76weeks of age. (B–C) Blood gluco
(D), and Δinsulin15 min/Δglucose15 min during an OGTT (E). (F) Kaplan-Meier analysis of severe
from 76-week-old OLETF rats with or without PNx. Scale bar, 100 μm. (H) Quantitative analys
of insulin-positive cells). (I) PNx was conducted in OLETF rats that had developed severe hype
glucose (J) and insulin levels (K) during the OGTT. Statistical signiﬁcance was calculated u
Kaplan-Meier method and compared using log-rank tests. P b 0.05 indicates statistical sig
pancreatic denervation; OGTT, oral glucose tolerance test.adequately addressed this question. Since hypothalamic AMPK is nega-
tively regulated by leptin signaling, ATP, and glycogen (Long and
Zierath, 2006; Kahn et al., 2005; Polekhina et al., 2003; McBride et al.,TF rats. (A) OLETF rats underwent PNx or sham surgery (n = 10 each) at 32 weeks of age,
se levels (B), glucose concentrations at 2 h post-glucose injection (C), plasma insulin levels
hyperglycemia incidence. (G) Immunoﬂuorescent staining of insulin and TUNEL in islets
is of TUNEL staining. Apoptotic index = 100 × (number of TUNEL-positive cells / number
rglycemia (n = 3). OGTTs were performed before and after PNx surgery. (J and K) Blood
sing a Wilcoxon-Mann-Whitney test. Survival parameters were determined using the
niﬁcance. N.S. indicates no statistical signiﬁcance. Graphs display mean ± SEM. PNx,
Fig. 8. Proposed regulatory mechanism of ﬁrst-phase GSIS at re-feeding after long-term
fasting and during frequent feeding. First-phase GSIS is decreased after long-term fasting
but is fully induced in the unfasted state. This system results in the brain being supplied
with glucose as soon as possible after a fast while also facilitating effective storage of
surplus energy in insulin-sensitive tissues to prepare for upcoming fasting periods. The
hypothalamic AMPK-SNS-β cell neural axis is involved in this regulatory system. AMPK,
AMP-activated protein kinase.
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local decreases in glucose utilization and glycogen content in the hypo-
thalamus might activate hypothalamic AMPK during diabetes. Second,
the links between the brain-β cell neural axis and mechanisms previ-
ously reported to regulate ﬁrst-phase GSIS, such as the glucose-fatty
acid cycle (Zhou et al., 1996), insulin-dependent insulin secretion
(Kulkarni et al., 1999; Bouche et al., 2010), and the insulin granule dy-
namic theory (Seino et al., 2011), remain unclear. Third, the relationship
between the genetic variance of the α-adrenergic receptor type 2,
which is strongly associated with diabetes risk (Dupuis et al., 2010;
Tang et al., 2014), and fasting-induced inhibition of ﬁrst-phase GSIS is
also interesting. A human study demonstrated a fasting-dependent de-
crease in ﬁrst-phase GSIS during an FSIVGTT regardless of gender. We
thus examined the effects of long-term fasting and diabetes on ﬁrst-
phase GSIS inmale rats only. Furthermore, metabolism is altered during
long-term fasting. Therefore, it is possible that gender differences and
metabolic changes, in addition to activated sympathetic nerves, may
be associated with longer fasting-dependent and diabetes-related de-
creases inﬁrst-phaseGSIS. Future studies to clarify these issueswill pro-
vide a better understanding of type 2 diabetes pathogenesis.
Another limitation of this study relates to how metabolic change in
response to fasting differs among species. For example, in a recent re-
port, lipidomic analysis of human and animal plasma showed that
lipid metabolism differed markedly between humans and rats during
fasting (Ishikawa et al., 2015). In our study, we examined the regulatory
mechanismofﬁrst-phaseGSIS only in rats, and did not conﬁrmourﬁnd-
ings in humans. Species-dependent variation inwhole-body energyme-
tabolism during fasting may inﬂuence the regulatory mechanism of
ﬁrst-phase GSIS differently in humans and rodents, although both
showed a signiﬁcant decrease in ﬁrst-phase GSIS after fasting.
Our results demonstrated that the physiological role of biphasic GSIS
is to overcome fasting, and that the fasting-induced decrease in ﬁrst-
phase GSIS is linked to the pathogenesis of β cell dysfunction in type 2
diabetes. Modulating this pathogenic alterationwith surgical pancreatic
denervation may be a promising therapy for type 2 diabetes. Further-
more, this study suggests that the detailed physiology of glucose-insulin
metabolism at the moment of re-feeding after fasting, as well as during
fasting alone, may increase knowledge of type 2 diabetes pathogenesis
and lead to potential therapies for the disease.
Supplementary data to this article can be found online at doi:10.
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